Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up

"Background: To report the 12-month anatomic and ETDRS best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin®) (1.25 mg or 2.5 mg) in patients with diffuse diabetic macular edema (DDME). In addition, a comparison of the two different doses of intravitreal...

Descripción completa

Detalles Bibliográficos
Autores Principales: "Arevalo, J. Fernando, Sanchez, Juan G., Fromow-Guerra, Jans, Wu, Lihteh, Berrocal, Maria H., Farah, Michel E., Cardillo, Jose, Rodríguez, Francisco J., for the Pan-American Collaborative Retina Study Group (PACORES)"
Formato: Artículo (Article)
Lenguaje:Inglés (English)
Publicado: 2009
Materias:
Oct
Acceso en línea:https://repository.urosario.edu.co/handle/10336/24173
https://doi.org/10.1007/s00417-008-1034-x